Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

Abstract excerpt

The myelodysplastic syndromes (MDSs) are a heterogeneous collection of clonal hematopoietic malignancies that compromise a large subgroup of the myeloid neoplasms and collectively are the most common acquired adult bone marrow failure syndromes. Currently, only 3 agents are approved for the treatment of MDS by the US Food and Drug Administration (FDA): azacitidine, decitabine, and lenalidomide. The latter drug,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Azacitidine
• Share to Decitabine
• Share to Drug Approval